T-cell engager vs stem cell transplant for newly diagnosed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma within the last 12 months.
- You are healthy enough for a stem cell transplant and have already had your own stem cells collected.
- You have completed 16 to 24 weeks of initial therapy (including a proteasome inhibitor, lenalidomide, and a CD38 antibody) and your disease responded at least partially.
- You have measurable disease (certain levels of M-protein in blood or urine) to track treatment response.
- You are willing to use effective birth control (if applicable) and follow specific safety monitoring programs.
- You do not have certain other active cancers, severe heart/lung conditions, or active infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
This trial compares standard stem cell transplant (ASCT) versus ASCT followed by a single infusion of your own immune cells engineered to attack myeloma cells (anti-BCMA CAR-T). It is for people who are newly diagnosed and eligible for a transplant.
This trial tests two different combinations of medicines in people who still have signs of multiple myeloma after a stem cell transplant. One group gets teclistamab and talquetamab, and the other gets daratumumab and lenalidomide. The goal is to see which works better at removing any remaining cancer cells.
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
Hear when a new Multiple Myeloma, Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.